Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02265419
Other study ID # A 2014-0064
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 2014
Est. completion date March 2022

Study information

Verified date April 2020
Source University of Rostock
Contact Martin Sauer, PD Dr.
Phone 49 381 4946409
Email martin.sauer@uni-rostock.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Heart-surgery with the use of a heart-lung-machine can trigger the development of a full-blown SIRS (Systemic Inflammatory Response Syndrom) with multi organ failure and severe sepsis in the course of disease.

For the treatment of full-blown SIRS extracorporeal treatment like the Cytosorb-Adsorber are in clinical testing. The Cytosorb-Adsorber is a CE-signed medical device with approval for the treatment of severe sepsis and hyperinflammation. The adsorber remove not-specific cytokines and other inflammation mediators from the patients blood.

In this study (as a case-observation and compassionate use) the effect of extracorporeal treatment with the Cytosorb-Adsorber for the reduction of postoperative hyperinflammation and SIRS after heart-surgery with use of a heart-lung-machine will be observed.

The aim of the study is recording the influence of the treatment with the Cytosorb-Adsorber on the course of hyperinflammation and multi organ failure in comparison with a historic control group.


Description:

All patients underlying heart surgery with the use of a heart-lung-machine and fullfilling of the inclusion-criteria should be sreened for the study. The study take place on two surgical intensive care units (PIT I and PIT II) of the university hospital Rostock, Germany. The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after end of the operation if written informed consent was obtained from all participants or from the patients` representatives if direct consent could not be received. The extracorporeal treatment duration will be 24 hours and the observation time 90 days.

The aim of the study is recording the influence of the treatment with the Cytosorb-Adsorber on the course of hyperinflammation and multi organ failure in comparison with a historic control group. The main-criterion is a significant difference in the mean-SOFA (Sequential Organ Failure Assessment)-score between the Cytosorb-group and the historic control group after 7 days. Beside criterions are the 30- and 90-day survival, time of respirator-therapy, length of ICU stay, severity of the Critical Illness Polyneuropathy and dosage of vasopressors on the days 1, 2 and 3.

From all patients basic demographic information, illness severity (APACHE II, SOFA scores), microbiological results, pre-morbidity, and clinical outcome for study cohort will recorded. At the days 1-4, 7, 14, 30 and before/after the extracorporeal treatment the patients will screened for clinical and immunological data: hemodynamic, inflammation, coagulation, hemolysis, temperature, organ function blood parameters and cytokines. "Day 1" was defined as the day of the beginning of the extracorporeal treatment. At days 1, 2 and 7 hemodynamic monitoring will done with the PiCCO-System (PULSION Medical Systems, Feldkirchen, Germany). For dynamic measurement of the liver function will used the LiMON-System (based on the indocyanin green plasma disappearance rate, PULSION) on the days 1, 2 and 7.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date March 2022
Est. primary completion date January 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- After heart surgery with heart-lung-machine

- 2 or more positive SIRS criterions within 6 hours postoperative

- need of > 1,9 liter kristalloids within 6 hours postoperative

- centralvenous oxygen saturation >75% within 6 hours postoperative

- need of vasopressors (=0,06 µg/Kg/Min) within 6 hours postoperative

Exclusion Criteria:

- Bleeding

- Thrombocyten < 20.000 /µl, INR>3,0

- HIV-Test positive

- Hepatitis C positive

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Extracorporeal treatment with the Cytosorb adsorber
The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after heart surgery operation, the extracorporeal treatment duration will be 24 hours and the observation time 90 days.

Locations

Country Name City State
Germany Intensive Care Units PIT 1+2, University hospital Rostock Rostock

Sponsors (1)

Lead Sponsor Collaborator
University of Rostock

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary mean SOFA A significant difference in the mean-SOFA (Sequential Organ Failure Assessment)-score between the Cytosorb-group and the historic control group after 7 days. day 7
Secondary 30- and 90-day survival Observation time 90 days. day 30, day 90
Secondary time of respirator-therapy Observation time 90 days. day 90
Secondary length of ICU stay Observation time 90 days. day 90
Secondary dosage of vasopressors on the days 1, 2 and 3. Use of Vasopressors are monitored. day 1, 2 and 3
See also
  Status Clinical Trial Phase
Recruiting NCT02906345 - TPE in Septic Patients and Influence on Organ Failure N/A
Completed NCT01937676 - LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting N/A
Not yet recruiting NCT04356300 - Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection N/A
Terminated NCT03895853 - Early Metabolic Resuscitation for Septic Shock Phase 2
Recruiting NCT04094428 - Burden, Mortality and Supply Costs in Intensive Care Unit Patients
Recruiting NCT02587273 - The Pharmacokinetics of Fentanyl in Intensive Care Patients Phase 4
Completed NCT01810328 - A Validation of a Genomics Based Prognostic in Severe Trauma N/A
Not yet recruiting NCT06371677 - Polish Nationwide Register of Hospitalized Patients in Cardiac Intensive Care Units
Recruiting NCT05182723 - Evaluation of the Effectiveness of Extracorporeal Methods for Removing Mediators of Systemic Inflammation N/A
Completed NCT00257231 - Inflammation and the Host Response to Injury (Trauma)
Recruiting NCT04306419 - Observational Trial on Cytokine Adsorption in Sepsis
Completed NCT02998931 - Trial of Enteral Glutamine on Clinical Outcomes in Critically Ill Patients Phase 3
Not yet recruiting NCT06340269 - Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF N/A
Not yet recruiting NCT01828372 - Quantification of Drugs and Their Degradation Products N/A
Completed NCT00118664 - Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children N/A
Completed NCT02706314 - Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.
Completed NCT02455180 - Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients Phase 4
Recruiting NCT02095444 - Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection Phase 1/Phase 2
Active, not recruiting NCT02858778 - Timing of Acute Palliative Care Consultation in Critically Ill Patients N/A
Recruiting NCT01363635 - Severe Sepsis/Septic Shock on Admission to the General Surgical ICU